Cancer treatment pioneer Nanobiotix (EPA:NANO) made good progress in the first half of 2017, Philippe Mauberna, chief financial officer said today.
The Paris-based company is developing the use of a combination of nanoparticles/radiotherapy to treat a range of cancers.
Mauberna pointed to the recent recommendation for the Phase II/III trial in Soft Tissue Sarcoma to continue and the successful clinical results from the Phase I/II Trial of lead product NBTXR3 in head & neck cancer.
A €25mln funding in April will enable the group to expand NBTXR3's clinical programme in head and neck cancer and take the Immuno-Oncology programme into patients, he added.
Revenues in the six months to June were €1.9m (H1 (€3.0m) with an after tax loss of €12mln (€10mln).
Cash at the end of June was €31mln (H1 2016: €25mln).